This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: March 31st, 2011 - March 31st, 2012

Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with MM.

Target Audience
The educational design of this activity addresses the needs of physicians, nurses, and pharmacists involved in the treatment of patients with multiple myeloma (MM).

Learning Objectives
After completing this activity, the participant should be better able to:

• Describe the latest diagnostic and staging criteria for SMM, MGUS, and MM to determine appropriate management strategies
• Identify factors that affect the choice of induction therapy for transplant- and non-transplant-eligible patients with MM
• Assess the clinical benefit of novel therapies used in the front-line treatment of MM, including improved response rates and prolonged survival

Agenda - 1.25 hours
• Articles/Commentaries: 60 minutes
• Evaluation/Post-Test: 15 minutes

Physician Continuing Education Accreditation
This activity has been planned and implemented in accordance with the  Essential Areas and Policies of the Accreditation Council for Continuing Medical Edu cation (ACCME) through the joint sponsorship of Global Education Group (Global) and Medical Learning Institute, Inc. (MLI). Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation
Global designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Registered Nurse Designation
Medical Learning Institute, Inc.
Provider approved by the California Board of Registered Nursing, Provider 15106, for 1.25 contact hours.

Registered Pharmacy Designation
MLI is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Completion of this activity provides for 1.25 contact hours (0.125 CEUs) of continuing education credit. The universal activity number for this activity is 0468-9999-11-009-H01-P.

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosures
*Charise Gleason, MSN, ANP-BC, AOCNP is a consultant for Merck.

*R. Donald Harvey III, PharmD, BCPS, BCOP, FCCP has nothing to disclose.

*Jonathan L. Kaufman, MD  is a consultant for Millennium Pharmaceuticals, Inc., has received research support from Celgene and Merck, is on a protocol review committee for Keryx, and is on an advisory committee for Onyx.

*Sagar Lonial, MD is a consultant for Bristol-Myers Squibb,  Celgene, Merck, Millennium Pharmaceuticals, Inc., Novartis, and Onyx.

*Content will include non-FDA-approved uses.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Disclaimer
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.